Multimodality Cardiovascular Imaging for the Translation of Therapies for Vascular Activation After MI

Part of paid clinical trials in Charlottesville, Virginia.

Sponsor
University of Virginia
Study ID
NCT05880355
Phase
EARLY_PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Myocardial Infarction

Eligibility Criteria

Sex
ALL
Age
25 Years - 99 Years
Healthy Volunteers
Not accepted

Interventions

  • Dapansutrile — DRUG
    Oral inhibitor of NLRP3
  • Placebo — OTHER
    Non-active placebo

Study Details

Subjects with urgently reperfused type I myocardial infarction (MI) will be recruited and randomized to receive either placebo or the oral inflammasome (NLRP3) inhibitor dapansutrile. The primarily outcome measure will be carotid plaque volume change over 6 months; secondary outcome measures will be plaque inflammatory activity and coronary microvascular function.

Key Dates

Start date
Apr 1, 2026
Status verified
May 2025
Primary completion
Dec 31, 2028
Completion
Jan 30, 2029

Study Design

Enrollment
60 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Dapansutrile
    Subjects randomized to receive oral dapnsutrile
  • Placebo Comparator: Control
    Subjects randomized to receive oral placebo

Primary Outcome Measure

Remote plaque volume [ Time Frame: 6 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of VirginiaCharlottesvilleVirginia22908-

Find similar trials in Charlottesville, VA

By research site
University of Virginia· Charlottesville, VA

Related Studies